A quasi-markov model for transmission and disease elimination: Hepatitis C among people who inject drugs

Rachel Hart-Malloy^{1†} and Gregory DiRienzo^{2†}

*Correspondence: adirienzo@albany.edu

CrossMark

Click for updates

[†]These authors contributed equally to this work.

¹AIDS Institute, New York State Department of Health, Albany NY; Department of Epidemiology and Biostatistics, University at Albany, State University of New York, Rensselaer, USA.

²Department of Epidemiology and Biostatistics, University at Albany, State University of New York, Rensselaer, USA.

Abstract

Background: The use of mathematic modeling to better understand the spread of Hepatitis C and the impact of interventions can be invaluable for localities, states and countries with a large burden of injection drug use. New York State (NYS) is estimated to be home to a large number of people who inject drugs (PWID), however the burden of hepatitis C among this population and the impact of interventions are not known and/or fully understood. Since accurate modeling can be complex and require costly data analysis software to implement, the purpose of this paper was to derive a methodology to accurately model the prevalence of hepatitis C at the state level that is tractable and easily implemented with free software.

Methods: A *non-stationary quasi-Markov* model, is proposed that is implemented using free software R[®]. The methodology aims to estimate hepatitis C prevalence and evaluate impacts of interventions on disease burden among PWID in NYS. The approach is “quasi-Markov” because transition probabilities among states change in time and depend on past information. Interventions evaluated aimed to: reduce sharing needles and/or other drug use paraphernalia; increase needle disinfection rates; and increase availability of clean needles and other drug use paraphernalia.

Results: The quasi-Markov model estimated hepatitis C prevalence among PWID reached an equilibrium value of 63.6 percent after 50 years. In order to eliminate disease, all proposed interventions were needed, resulting in an estimated prevalence less than 1.0 percent, 56 years after implementation. Using parameters defined for an alternate study modeling hepatitis C prevalence found similar results, serving to reinforce the validity of the proposed methods.

Conclusion: The results of this analysis demonstrate the feasibility of using a non-stationary quasi-Markov methodology to model the spread of hepatitis C among PWID using free programming software. Coding provided can be used by other researchers to use and modify for their own purposes and could further impact this field of research as well as inform and promote additional education prevention and interventions for PWID.

Keywords: Hepatitis C virus, markov modeling, injection drug use, people who inject drugs

Introduction

Hepatitis C virus (HCV) infection, estimated to be the most common chronic blood borne infection in the United States (US), has been shown to disproportionately affect people who inject drugs (PWID) [1-3]. Whereas prevalence estimates among the general US population ranges from 1.0 to 1.6 percent, prevalence estimates among PWID range from 40 to 90 percent [1-8]. HCV transmission among PWID can result from, but not limited to, sharing needles or other drug use paraphernalia

(i.e., cookers, cotton, or rinse water; referred to as equipment) [9-11]. Individuals may be asymptomatic for decades and if left untreated, HCV infection can lead to cirrhosis of the liver, liver failure, hepatocellular carcinoma and death [12,13]. PWID, in particular, are at an even greater risk of the morbidity and mortality associated with untreated HCV because they often times do not have access to the healthcare system [3,8,14,15]. HCV prevention and interventions targeted towards PWID have included behavioral interventions, substance use treatment,

syringe exchange or access programs, needle disinfection and multi-component interventions [8]. The impacts of these interventions on reducing transmission risk are not fully understood since corresponding studies have varying results [8,16,17]. One meta-analysis found that of the interventions examined, the use of a combination of prevention strategies, or multi-component interventions, were most effective, however; this was based on only two studies neither of which were conducted in the US [8].

Mathematical models have been used to estimate HCV incidence and prevalence among PWID as well as to model the effect of interventions and HCV treatment [18-21]. The use of modeling to better understand the spread of HCV and the impact of interventions can be invaluable for localities, states and countries with a large burden of injection drug use (IDU). New York State (NYS) is estimated to be home to a large number of PWID, however the burden of HCV among this population and the impact of interventions are not fully understood [22-28].

Given that modeling can be complex and require costly data analysis software, the purpose of this paper was to derive a methodology to model the prevalence of HCV that is accurate, easily understood and implemented with free software (R®). The methodology is designed specifically to better understand HCV disease burden among PWID, and permit evaluation of the impact of interventions on the HCV burden at a state level. In an effort to better serve the larger population of PWID, a secondary purpose of this research was to provide annotated R® coding for other states and localities to conduct similar research and thus broaden the reach of this analysis. All coding for the model was written using R® version 2.14.1 (source code provided as a [Supplement Data](#)).

Methods

Study design

Non-stationary quasi-Markov modeling was utilized to estimate HCV prevalence and to assess the impact of interventions on disease elimination among PWID in NYS. The structure of the model was motivated from those results of Corson, et al., 2012, who utilized a deterministic compartmental model for HCV transmission [19]. Although the results of Corson, et al., 2012 are very valuable, their approach is somewhat sophisticated by way of use of deterministic differential equations that require high powered computing to implement, both of which may present a barrier to general researchers in this field for a thorough understanding and tractable implementation. Similar to Corson, et al., we defined a model whereby individuals transition between a set of possible predefined states through time. However, our approach uses a tractable and somewhat simple stochastic framework based on Markov modeling for governing transitions between states and is easily implemented with free software ([Supplement Data](#)). Possible routes of HCV infection modeled were through needle and equipment sharing only. The natural history of HCV was developed based

upon previous literature and includes basic states of the disease which will be described in more detail below ([Figure 1](#)) [20]. The transition probabilities between states of HCV were dependent upon virologic parameters of the disease, such as the probability of spontaneously clearing the infection, and also parameters determined based upon characteristics of the population, such as the prevalence of HCV among PWID. For this reason, transition probabilities between states were non-stationary, meaning they were updated at each time unit to accommodate the changing parameters of the PWID population. The time unit chosen for this analysis was days, which we think realistically accommodates the real world behaviors in this population, and estimates were modeled over 75 years (27,375 days), which in our opinion is an acceptable time range based on expected human life span. Time zero is a theoretical year in which the PWID population is defined by the assumptions of the model, explained in more detail below, and is not intended to reflect a specific calendar year.

Quasi-markov model transition probabilities and parameters

A graphic showing the possible states of the progression of HCV and the allowable transitions between states is provided in [Figure 1](#). The probability that PWID transition from susceptible state (x) (i.e., never infected with HCV) to acutely infected (state h_1 or h_2) was based upon the probability of infection at time t , $p(t)$ (defined as risk of infection due to sharing needles or equipment) [19]. In general terms, the probability of infection at time t depends upon a combination of the probabilities that an individual shares needles or equipment, the shared needle is not cleaned, the un-cleaned needle or equipment shared is infected, and lastly, the infected, shared and un-cleaned needle or equipment successfully transmits the disease during that sharing encounter. These probabilities are inherently dependent upon the proportion of the population that is acutely infected or chronically infected (state y) as well as the proportion of needles and equipment available. More specifically, the probability of infection experienced by the susceptible population is driven by the probability per day that the individual shares needles (λ_N) or equipment (λ_E), the probability that they do not clean needles ($1-\phi$), the probability that the specific needle or equipment used will transmit infection successfully (ψ_{Ns}, ψ_{Es}) and the proportion of infected needles ($\beta_{Ns}(t)$) and equipment ($\beta_{Es}(t)$) in the PWID population at time t , where s can be either h_1 , h_2 or y and, ($\psi_{Nh1,h2}, \psi_{Eh1,h2}$) refers to the probability of successful acute transmission when sharing needles and equipment, respectively ([Table 1](#)).

$$p(t) = \lambda_N (1 - \phi) (\psi_{Nh1,h2} (\beta_{Nh1}(t) + \beta_{Nh2}(t)) + \psi_{Ny} \beta_{Ny}(t)) + \lambda_E$$

$$(\psi_{Eh1,h2} (\beta_{Eh1}(t) + \beta_{Eh2}(t)) + \psi_{Ey} \beta_{Ey}(t))$$

The proportion of infected needles was dependent upon the

average number of injections per day (2.8) [37] and the average number of needles in NYS: 1) dispensed through syringe exchange programs (SEPs) (from 2002-2011); and 2) sold through the expanded syringe access program (ESAP) (Table 1) [30,38]. See Corson et al., for derivation of the proportion of infected needles [19]. The proportion of infected equipment was dependent upon the amount of equipment dispensed from SEPs. For the purpose of this analysis, equipment was considered to include cotton, cookers and rinse water. A determination of this quantity is not available. Therefore, the ratio of the amount of equipment available to the number of needles dispensed or sold was assumed to be 3:4 based on feedback from SEPs. This was varied in a sensitivity analysis,

Table 1. Parameters to model hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) in New York State (NYS).

Parameter	Definition [source(s)]	Value
n	Number of PWID in NYS [29]	133,392
s	Number of needles dispensed/sold in NYS in a year [30]*	5,083,444
λ_N	Probability of sharing needles per day [31]*	
	High risk	0.22
	Medium risk	0.00
	Low risk	0.00
λ_E	Probability of sharing equipment per day [31]*	
	High risk	0.40
	Medium risk	0.51
	Low risk	0.03
ϕ	Probability of successfully cleaning needle prior to use [32]*	0.145
μ	Rate that PWIDs leave population per day [31]	0.00029
τ	Daily needle turnover rate: $\frac{s}{n*365.25}$	0.104
τ_1	Daily equipment turnover rate (proportion of needles dispensed or sold): $\tau*0.75$	0.078
γ	PWID to needle ratio: $\frac{n}{\text{needles in circulation daily}^* (\frac{\text{average number times needle used}^*}{\text{average injections per day}^*})}$	0.99981
ψ_{Ns}	HCV transmission probability per shared needle where $s \in \{h_1, h_2, h_3, y\}$ [31]:	
	acutely infected (h_1, h_2)	0.073
	chronically infected (y)	0.0073
ψ_{Es}	HCV transmission probability per equipment sharing event where $s \in \{h_1, h_2, h_3, y\}$ [31]:	
	acutely infected (h_1, h_2)	0.023
	chronically infected (y)	0.0023
$\beta_{Ns}(t)$	Proportion of infected needles where $s \in \{h_1, h_2, h_3, y\}$: proportion of persons in state s at time t $(1 + \frac{\tau}{\lambda_N \gamma})$	--
$\beta_{Es}(t)$	Proportion of infected equipment where $s \in \{h_1, h_2, y\}$: proportion of persons in state s at time t $(1 + \frac{\tau_1}{\lambda_E \gamma})$	--
δ	Proportion of PWIDs that resolve HCV infection [33-36]	0.234
α	Proportion of PWIDs who develop protective immunity [19]	0.250

*Modifiable parameters that reflect possible aims of interventions to reduce or eliminate HCV among PWID.

*See Corson, et al., for derivation of these parameters. (Corson et al., 2012).

*Values available upon request.

the details of which are described below.

Not all persons who become acutely infected develop

chronic HCV infection; a proportion of acutely infected persons spontaneously clear the virus within six months [39]. Therefore, based on previous work, two acute HCV states (h_1 , h_2) were included in the natural history model for which acutely infected individuals in state h_1 may progress to chronic HCV infection (state y) and acutely infected individuals in state h_2 may clear the infection and progress to a susceptible state of previously infected individuals (x_1) [19]. Given the time unit of days, new cases remain in state h_1 , h_2 for 180 days (six months). Only upon reaching day 180 does the model permit transition out of those states and into either state y or state x_1 thus creating a transition probability that is dependent upon ones state in the previous time iteration. That is, for $j=1, 2$, let denote the number of persons in state at day $t=0, \dots, 27,375$, where $t=0$ is the initial state and μ =the rate individuals leave the PWID population (Table 1). Then, for $t=1, \dots, 180$:

$$h_j(t) = \sum_{v=0}^{t-1} (h_j(v) - \mu)$$

and for $k=1, \dots, (27,375-180)$

$$h_j(180+k) = \sum_{v=k}^{180+k-1} (h_j(v) - \mu) - \sum_{v=0}^{k-1} (h_j(v) - \mu)$$

Some research has found that following spontaneous clearance of an acute infection a proportion of individuals may have protective immunity to re-infection; however, findings regarding a conferring of a protective immunity are equivocal [40-43]. In order to capture the possibility of some level of a protective immunity, a corresponding state (z) was included in the natural history model with a low transition probability (0.25) [19].

Inherent in the model at each time unit is the probability of leaving the PWID population (μ), represented by the state exit e_x . This transition is possible from all states of the natural history (including during the first 180 days of an incident case). Research has shown that the probability of an individual leaving the population is roughly equivalent to the probability of new individuals entering the population [31,44]. Thus, the proportion of the population that transitions to state e_x is set to equal the proportion of the population added into susceptible state, x , at the end of each time iteration (a 1-to-1 replacement of those who left with those who enter). This decision was made solely for modeling purposes and does not reflect an individual leaving the population (regardless of infection status) and re-entering as susceptible. The parameters and the sources used to define the annual transition probabilities are in Table 1.

Analysis

The quasi-Markov model in Figure 1 was utilized to model HCV prevalence among PWID through needle and equipment sharing (model 1). To determine what interventions would be needed to eliminate HCV from the population, modifications using a basic reproductive number (R_0) were explored and the

initial model was altered to determine the effects different interventions would have on HCV prevalence over time (model 2).

Modeling HCV prevalence: model 1

Using the defined probabilities, the population distribution of PWID in NYS at time $t=0$ was assumed to be 99.0 percent susceptible (x) and 1.0 percent acutely infected only (state h_1). This is to reflect an assumption that only a small proportion of the population is infected at time $t=0$. The probability that an individual shares needles and/or equipment per day was allowed to vary in the model based upon the proportion of the PWID population considered to be high (0.38), medium (0.19) or low risk (0.43) [31]. This distribution of PWID risk groups was informed by their needle and equipment sharing behaviors, as determined from the literature (Table 1) [31]. These probabilities were assumed to be held constant over time. Using the R® code developed for this analysis (Supplement Data), the population was projected through 75 years (27,375 time units). At each time point, the updated prevalence in each state was calculated as:

$$\begin{aligned} &[x(t+1), h_1(t+1), h_2(t+1), x_1(t+1), z(t+1), y(t+1), x_2(t+1)] = \\ &[x(t), h_1(t), h_2(t), x_1(t), z(t), y(t), x_2(t)] M(t) \end{aligned}$$

Where the transition matrix $M(t)$ is defined in Figure 1.

HCV prevalence among the individuals was defined as those who have ever been infected, or those who would be defined as HCV antibody positive (anti-HCV), therefore summing the prevalence of individuals in the following states: h_1 , h_2 , x_1 , y , and z .

Several sensitivity analyses were conducted. First, the ratio of available equipment to needles dispensed or sold in NYS was varied from 1:1 to 1:10. Second, rather than assume 99.0 percent of the population was susceptible (x) at time $t=0$, the proportion susceptible (x) was varied from as low as 70.0 to as high as 99.9 to determine any differences in the prevalence once reaching equilibrium. Third, given the equivocal nature of protective immunity, the model was evaluated removing this state in the natural history. Lastly, the model was run assuming the proportion of individuals who spontaneously clear the infection (probability of transitioning from susceptible (x , x_1) to acutely infected (h_1)) was larger based upon results presented in the literature (0.26 compared to 0.23) [42].

Modeling disease elimination through modifying parameters: model 2

Modifiable parameters assessed were: 1) reducing the amount of needle and equipment sharing (λ_N , λ_E); 2) increasing the proportion of PWID who properly sterilize needles (ϕ); 3) increasing the number of needles dispensed or sold in a given year and; 4) increasing the amount of equipment dispensed in a given year. To determine to what degree specific parameters

would need to be modified to eliminate HCV, defined here as a prevalence of less than 1%, a formula for the basic reproductive number (R_0) was used. The number R_0 is defined as number of secondary infections resulting from an infected individual. Briefly, when $R_0=1$, each infected individual is responsible for infecting another individual; therefore, when $R_0<1$, a disease will theoretically die out and when $R_0>1$, a disease will reach an epidemic level. The formula used for our purposes was based on a version of a previously derived equation for R_0 determined by Corson, et al., which was modified to include information on both needle and equipment sharing [19]. In brief, the formula derived by Corson, et al., defines R_0 as the expected number of infections resulting from an infectious needle multiplied by the expected number of needles generated by a PWID during their infectious lifetime. For our purposes, using the parameters defined for this study, R_0 was modified to incorporate the expected number of infections resulting from infectious equipment multiplied by the expected number of equipment (considered as cotton, cooker and water, as defined above) generated by a PWID during their infectious lifetime:

$$R_0 = \frac{(\lambda_N * 365.25)(1-\phi)}{(\mu * 365.25)[(\mu * 365.25) + \sigma][1 + (\tau * 365.25)]} [(\mu * 365.25)\psi_{Nk} + \psi_{Ny}\sigma(1-\delta)] + \frac{(\lambda_E * 365.25)}{(\mu * 365.25)[(\mu * 365.25) + \sigma][1 + (\tau_i * 365.25)]} [(\mu * 365.25)\psi_{Ek} + \psi_{Ey}\sigma(1-\delta)]$$

where $1/\sigma=0.5$, as defined by Corson, et al., represents the duration of an acute phase in years [19].

The number R_0 was calculated for low, medium and high risk PWID using the same behavioral and virologic parameters utilized in model 1. Assuming R_0 was greater than one (no disease elimination), it was determined how to adjust the parameters representative of the above described interventions in order to ensure that R_0 would be less than one (allowing disease elimination), thus creating the theoretical conditions necessary to eliminate HCV. Adjustments were made using an empirical trial and error process.

The parameters were then updated in model 1 to determine what prevalence would be over time given the interventions (model 2). The distribution of the population of PWID at time $t=0$ was defined based upon the resulting distribution from model 1. This population was then projected again through 75 years using the updated parameters. A sensitivity analysis was employed in which the ratio of available equipment to needles distributed or sold was varied from 1:1 to 1:10.

Results

HCV prevalence

Estimated prevalence among PWID in NYS from model 1 rose to over 50.0 percent within 25 years and reached equilibrium at 64.1 percent within 50 years (Figure 2). Varying the ratio of equipment to needles dispensed or sold from the original 3:4 to 1:1 and 1:10, respectively, resulted in prevalence ranging from 63.0 to 67.6 percent (results not shown). Prevalence was

not impacted when the proportion susceptible, x , at time $t=0$ was varied. When removing the transition probability for protective immunity, prevalence increased at a more rapid rate and reached a higher prevalence at equilibrium (65.8 percent) (Figure 2). When assuming the proportion that spontaneously clears the infection was higher, prevalence increased at a slower rate and the prevalence at equilibrium was lower at 63.3 percent (Figure 2).

Disease elimination

The basic reproductive number exceeded 1 for only the medium (4.3) and high risk groups (7.3). These parameters, referred to collectively as a multi-component approach, included modifying the parameters as follows: 1) reducing the probability of sharing needles in the high risk group by half (from a probability of 0.22 per day to 0.11 per day; the probability in the other risk groups was 0), 2) reducing the probability of sharing equipment in the high and medium risk groups by a quarter (from 0.40 and 0.51 to 0.10 and 0.13, respectively), 3) increasing the probability of cleaning one's needle in the high risk group by two-fold (from 0.145 to 0.290), 4) increasing the amount of equipment in the high and medium risk groups available by four-fold (from 3,812,583 to 15,250,332) and, 5) increasing the number of needles dispensed in the high and medium risk groups two and a half times (from 5,083,444 to 12,708,611). When prevalence was modeled assuming the above mentioned multi-component approach, the prevalence declined reaching 50.0 percent in less than 5 years (Figure 3). Upon reaching equilibrium, the prevalence was 0.2 percent. A visual display of the impact of each modified parameter is displayed in Figure 3.

Varying the ratio of available equipment to dispensed needles impacted what is required to eliminate disease and reach equilibrium. As would be expected, when assuming a 1:1 ratio, less equipment was needed to reach equilibrium (a three-fold and two-fold increase among the high and medium

risk groups were needed, respectively, compared to the four-fold increase for the initial analysis). When assuming a 1:10 ratio, to reach equilibrium, adjustments were needed for the high risk group only requiring an increase in both the amount of needles (needed to increase four-fold for the high risk group compared to 2.5 times for the initial analysis) and equipment (needed a six-fold for the high risk group compared to the four-fold increase for the initial analysis) and a reduction in the probability of sharing needles per day (reduced by one-third compared to one-half for the initial analysis).

Model validation

The prevalence of HCV among PWID in NYS is unknown and therefore cannot be used to validate the model. However, in an effort to validate the findings, our model was run on previously published work modeling prevalence of HCV [19]. Here, Corson, et al., modeled HCV prevalence in Glasgow, Scotland using a deterministic compartmental model using the dynamic systems modeling software Berkeley Madonna™. Contrary to our proposed methodology, the model used by Corson, et al., did not account for equipment sharing.

Therefore, for comparison purposes, prevalence was modeled by our proposed methods using the parameter values implemented by Corson, et al., where equipment sharing was not accounted for. In addition, since Corson, et al., utilized shared injections per year in their model, the parameters were adjusted to reflect to the probability of sharing per day for our proposed methodology.

The model used by Corson, et al., determined that HCV prevalence among PWID in Glasgow rose steadily for the

first decade reaching equilibrium around year 15 at an HCV prevalence of 68.9 percent. The resulting HCV prevalence results from our model using their parameters were similar with HCV prevalence rising steadily and reaching equilibrium later at year 35 at a slightly lower HCV prevalence of 62.1 percent. Although a similar prevalence was determined in Glasgow by Corson et al., as in NYS, the populations examined differed in several ways: the estimated number of PWID, the estimated number of needles distributed, the proportion of the population estimated to be sharing, and the probability of acute and chronic transmission per shared injection event. These differences thus resulted in differing PWID to needle ratios and needle turnover rate as well.

Modeling HCV prevalence when $R_0 < 1$, was also done in an effort to provide some validation. Similar to results found by Corson, et al., elimination was reached using the parameters necessary to meet $R_0 < 1$. However, the decline in prevalence was slower with our model reaching < 0.002 within in 35 years compared to 20 years as determined by Corson, et al.

In an effort to further validate the model, the estimate for HCV prevalence among PWID in NYS from this model was compared to other estimates among PWID. The prevalence of HCV among PWID has been cited to range between 40 and 90 percent, depending upon geography [8]. In addition, studies were done in the late 1990's and early 2000's in areas of New York City finding HCV prevalence ranging from 32-90 percent. The prevalence found in this study falls within the range of previous estimates [24,45,46].

Furthermore, the estimated number of secondary infections resulting from PWID belonging to the medium and high risks groups (4.3 and 7.3, respectively) is similar to other findings by Magiorkinis et al., (2013), who calculated R_0 in Greece for HCV subtypes using epidemiologic (surveillance) data and phylodynamic modeling [47]. For subtypes with a higher proportion of PWID, they estimated that the number of secondary infections were 3.4, 11.5 and 2.4 for subtypes 1a, 3a and 4a, respectively; the subtype with the highest proportion of PWID (47 percent) was subtype 3a [47]. The results from the present analysis thus fall within the range found by Magiorkinis et al., despite the differing methodologies.

Finally, two pathological cases were explored in an effort to validate the model in which the transmission probabilities were set to the unrealistic parameters of zero and 1. With the parameters set to zero, the steady-state prevalence went to zero; alternatively, with the parameters set to 1, likewise the steady-state prevalence went to 1 (i.e., all individuals would be infected).

Discussion

This study demonstrated that HCV prevalence can be estimated at the state level using a non-stationary quasi-Markov model run entirely using free software. To the best of our knowledge, this is the first study using a quasi-Markov model to estimate HCV prevalence. In addition, the other available methodologies

presented in the literature to estimate HCV prevalence require complex statistical analyses software packages that can be expensive. Although the model cannot be directly compared to existing NYS HCV prevalence among PWID due to lack of observed data, the results estimated an HCV prevalence within the range of other studies conducted in NYS and elsewhere among samples of PWID further supporting the validity of the method [8,24,45,46]. In addition, results from this methodology demonstrated that using a multi-component intervention model was needed to effectively eliminate HCV from the population. This supports other research on the effectiveness of such harm reduction strategies among PWID [8,48,49].

Although it is beyond the scope of the paper to assess or recommend interventions that would result in the modifications as specified to eliminate HCV among PWID in NYS, the parameters were intentionally chosen as “modifiable” in nature.

It must be noted that time in this analysis does not reflect prevalence over time in NYS among PWID. This model is used as a tool to see what prevalence could be assuming a small proportion of PWID are initially infected, accounting for current IDU behaviors, and needle and equipment distribution. The actual prevalence among PWID in NYS over time has likely been impacted by interventions implemented such as needle exchange and sale through SEPs and the ESAP, and the distribution of equipment by SEPs.

There are some limitations to this analysis. First, this study does not account for the possibility of dual infection, in which a person is infected with more than one HCV strain [50]. This could impact the probability of spontaneous clearance. Further analysis examining what impact this would have on disease spread and elimination are needed. Second, model 1, though taking into account other current interventions such as needle and equipment distribution, does not account for the possibility of HCV treatment. The proportion of active PWID who are treated is likely low, given low overall treatment in the general population, and would therefore only marginally lower the overall prevalence [51]. Third, parameters from localities other than NYS were used in this analysis. Although several studies conducted in NYS among PWID have been done, they have been restricted to areas in NY City and do not have the detailed level of information needed (daily probability of sharing needles and equipment, daily probability of cleaning ones needle, and daily rate that PWID exits population) to inform the parameters in our model. In addition, the prevalence of HCV among PWID in NYS is unknown and therefore cannot be used to validate the model. Although surveillance is currently conducted, risk factor data is not required for reporting purposes. Future studies conducted among PWID in NYS are needed and could be used to improve this study methodology. Fourth, the model does not specifically account for factors that may expedite the transition between disease stages such as alcohol use or HIV [13]. Given the large HIV epidemic in NYS, this could

impact the model [52]. Further modeling incorporating these factors should be done, for example, by modeling HIV positive and HIV negative persons who consume alcohol to assess the difference. Lastly, the amount of equipment available was assumed to be a percentage of the number of needles dispensed or sold. Although sensitivity analyses explored varying this ratio, knowledge of a more precise amount would benefit the analysis.

Conclusion

The results of this analysis demonstrate the feasibility of using non-stationary quasi-Markov modeling to model the spread of HCV among PWID using free programming software. The R[®] code in the appendix has been provided for other researchers to use and modify for their own purposes and could further impact this field of research as well as inform and promote additional education prevention and interventions for PWID.

Additional files

Supplement Data

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

Authors' contributions	RH	GD
Research concept and design	✓	✓
Collection and/or assembly of data	✓	✓
Data analysis and interpretation	✓	✓
Writing the article	✓	✓
Critical revision of the article	✓	✓
Final approval of article	✓	✓
Statistical analysis	✓	✓

Acknowledgement

We would like to thank Colleen Flanigan, Director of the Viral Hepatitis Section at the AIDS Institute New York State Department of Health, for her contributions to the conception and interpretation of this study. We are grateful to Maxine Philips, Barbara Agatstein and the Division of Prevention at the New York State Department of Health for providing us pertinent information regarding syringe exchange programs and for their expertise in the field.

Publication history

Editor: Guy Nathaniel Brock, University of Louisville, USA.

EIC: Jimmy Efrid, East Carolina University, USA.

Received: 27-Jun-2014 Final Revised: 27-Sep-2014

Accepted: 02-Oct-2014 Published: 07-Oct-2014

References

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL and Alter MJ. **The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.** *Ann Intern Med.* 2006; **144**:705-14. | [Article](#) | [PubMed](#)
2. Denniston MM, Jiles RB, Drobeniuc J, Kleven RM, Ward JW, McQuillan GM and Holmberg SD. **Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.** *Ann Intern Med.* 2014; **160**:293-300. | [Article](#) | [PubMed](#)

3. Edlin BR. **Perspective: test and treat this silent killer.** *Nature*. 2011; **474**:S18-9. | [Article](#) | [PubMed](#)
4. White EF, Garfein RS, Brouwer KC, Lozada R, Ramos R, Firestone-Cruz M, Perez SG, Magis-Rodriguez C, Conde-Glez CJ and Strathdee SA. **Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S.** *Salud Publica Mex*. 2007; **49**:165-172. | [Article](#)
5. Lorvick J, Kral AH, Seal K, Gee L and Edlin BR. **Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif.** *Am J Public Health*. 2001; **91**:46-47. | [Article](#)
6. Mitchell AE, Colvin HM and Palmer Beasley R. **Institute of Medicine recommendations for the prevention and control of hepatitis B and C.** *Hepatology*. 2010; **51**:729-33. | [Article](#) | [PubMed](#)
7. Garfein RS, Vlahov D, Galai N, Doherty MC and Nelson KE. **Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses.** *Am J Public Health*. 1996; **86**:655-61. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
8. Hagan H, Pouget ER and Des Jarlais DC. **A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.** *J Infect Dis*. 2011; **204**:74-83. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
9. Doerrbecker J, Behrendt P, Mateu-Gelabert P, Ciesek S, Riebeschl N, Wilhelm C, Steinmann J, Pietschmann T and Steinmann E. **Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment.** *J Infect Dis*. 2013; **207**:281-7. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
10. Zibbell J. **Safer Injection 2.0: Beyond the Point.** *Harm Reduction Communication*. 2012. | [Pdf](#)
11. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS and Alexander ER. **Sharing of drug preparation equipment as a risk factor for hepatitis C.** *Am J Public Health*. 2001; **91**:42-6. | [PubMed Abstract](#) | [PubMed Full Text](#)
12. El-Kamary SS, Jhaveri R and Shardell MD. **All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population.** *Clin Infect Dis*. 2011; **53**:150-157. | [Article](#)
13. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD and Lesesne SB. **Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States.** *Dig Liver Dis*. 2011; **43**:66-72. | [Article](#) | [PubMed](#)
14. Braitstein P, Li K, Kerr T, Montaner JS, Hogg RS and Wood E. **Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone.** *AIDS Care*. 2006; **18**:690-3. | [Article](#) | [PubMed](#)
15. Cisneros GO, Douaihy AB and Kirisci L. **Access to Healthcare Among Injection Drug Users at a Needle Exchange Program in Pittsburgh, PA.** *J Addict Med*. 2009; **3**:89-94. | [Article](#) | [PubMed](#)
16. Grebely J and Dore GJ. **Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity.** *J Infect Dis*. 2011; **203**:571-4. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
17. Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, May M, Taylor A, De Angelis D, Cameron S, Parry J, Lyons M, Goldberg D, Allen E and Hickman M. **The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.** *Addiction*. 2011; **106**:1978-88. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
18. Hellard ME, Jenkinson R, Higgs P, Stooove MA, Sacks-Davis R, Gold J, Hickman M, Vickerman P and Martin NK. **Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.** *Med J Aust*. 2012; **196**:638-41. | [Article](#) | [PubMed](#)
19. Corson S, Greenhalgh D and Hutchinson S. **Mathematically modelling the spread of hepatitis C in injecting drug users.** *Math Med Biol*. 2012; **29**:205-30. | [Article](#) | [PubMed](#)
20. Vickerman P, Hickman M and Judd A. **Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study.** *Int J Epidemiol*. 2007; **36**:396-405. | [Article](#) | [PubMed](#)
21. Martin NK, Vickerman P and Hickman M. **Mathematical modelling of hepatitis C treatment for injecting drug users.** *J Theor Biol*. 2011; **274**:58-66. | [Article](#) | [PubMed](#)
22. Brady JE, Friedman SR, Cooper HL, Flom PL, Tempalski B and Gostnell K. **Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002.** *J Urban Health*. 2008; **85**:323-51. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
23. Cortland sees spike in Hepatitis C in drug users. | [Article](#)
24. Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, Smith L, Wethers J, Milliken J, Mildvan D, Yancovitz S and Friedman SR. **Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001.** *AIDS*. 2005; **19** Suppl 3:S20-5. | [Article](#) | [PubMed](#)
25. Cooper H, Friedman SR, Tempalski B, Friedman R and Keem M. **Racial/ethnic disparities in injection drug use in large US metropolitan areas.** *Ann Epidemiol*. 2005; **15**:326-34. | [Article](#) | [PubMed](#)
26. Cooper HL, Brady JE, Friedman SR, Tempalski B, Gostnell K and Flom PL. **Estimating the prevalence of injection drug use among black and white adults in large U.S. metropolitan areas over time (1992-2002): estimation methods and prevalence trends.** *J Urban Health*. 2008; **85**:826-56. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
27. Tempalski B, Lieb S, Cleland CM, Cooper H, Brady JE and Friedman SR. **HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002.** *J Urban Health*. 2009; **86**:132-54. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
28. Friedman SR, Tempalski B, Cooper H, Perlis T, Keem M, Friedman R and Flom PL. **Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users.** *J Urban Health*. 2004; **81**:377-400. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
29. Tempalski B, Pouget ER, Cleland CM, Brady JE, Cooper HL, Hall HI, Lansky A, West BS and Friedman SR. **Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007.** *PLoS One*. 2013; **8**:e64789. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
30. Tesoriero JM, Battles HB, Klein SJ, Kaufman E and Birkhead GS. **Expanding access to sterile syringes through pharmacies: assessment of New York's Expanded Syringe Access Program.** *J Am Pharm Assoc* (2003). 2009; **49**:407-16. | [Article](#) | [PubMed](#)
31. Hahn JA, Wylie D, Dill J, Sanchez MS, Lloyd-Smith JO, Page-Shafer K and Getz WM. **Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users.** *Epidemics*. 2009; **1**:47-57. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
32. Korthuis PT, Feaster DJ, Gomez ZL, Das M, Tross S, Wiest K, Douaihy A, Mandler RN, Sorensen JL, Colfax G, McCarty D, Cohen SE, Penn PE, Lape D and Metsch LR. **Injection behaviors among injection drug users in treatment: the role of hepatitis C awareness.** *Addict Behav*. 2012; **37**:552-5. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
33. Davis GL, Albright JE, Cook SF and Rosenberg DM. **Projecting future complications of chronic hepatitis C in the United States.** *Liver Transpl*. 2003; **9**:331-8. | [Article](#) | [PubMed](#)
34. Seeff LB. **Natural history of hepatitis C.** *Am J Med*. 1999; **107**:10S-15S. | [Article](#) | [PubMed](#)
35. Santantonio T, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, Leandro G and Pastore G. **Natural course of acute hepatitis C: a long-term prospective study.** *Dig Liver Dis*. 2003; **35**:104-13. | [Article](#) | [PubMed](#)
36. Deuffic S, Buffat L, Poynard T and Valleron AJ. **Modeling the hepatitis C virus epidemic in France.** *Hepatology*. 1999; **29**:1596-601. | [Article](#) | [PubMed](#)
37. Lurie P, Jones TS and Foley J. **A sterile syringe for every drug user injection: how many injections take place annually, and how might pharmacists contribute to syringe distribution?** *J Acquir Immune Defic Syndr Hum Retrovirol*. 1998; **18** Suppl 1:S45-51. | [Article](#) | [PubMed](#)
38. Division of HIV/STD/Hep C Prevention, AIDS Institute, New York State Department of Health: **Number of syringes dispensed in New York State through Syringe Exchange Programs.** Personal Communication. March 14, 2012.

39. Chen SL and Morgan TR. **The natural history of hepatitis C virus (HCV) infection.** *Int J Med Sci.* 2006; **3**:47-52. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
40. Grebely J, Knight E, Ngai T, Genoway KA, Raffa JD, Storms M, Gallagher L, Krajden M, Dore GJ, Duncan F and Conway B. **Reinfection with hepatitis C virus following sustained virological response in injection drug users.** *J Gastroenterol Hepatol.* 2010; **25**:1281-4. | [Article](#) | [PubMed](#)
41. Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, Page K, Lloyd AR and Dore GJ. **Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine.** *Lancet Infect Dis.* 2012; **12**:408-14. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
42. Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I, Kaldor JM, White PA and Dore GJ. **High incidence of hepatitis C virus reinfection within a cohort of injecting drug users.** *J Viral Hepat.* 2007; **14**:413-8. | [Article](#) | [PubMed](#)
43. Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, Drummer H and Hellard M. **High incidence of hepatitis C virus reinfection in a cohort of injecting drug users.** *Hepatology.* 2008; **48**:1746-52. | [Article](#) | [PubMed](#)
44. Micallef JM, Kaldor JM and Dore GJ. **Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.** *J Viral Hepat.* 2006; **13**:34-41. | [Article](#) | [PubMed](#)
45. Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, Rockwell R, Edwards V, Friedman SR, Monterroso E, Williams I and Garfein RS. **Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City.** *Am J Epidemiol.* 2003; **157**:467-71. | [Article](#) | [PubMed](#)
46. Diaz T, Des Jarlais DC, Vlahov D, Perlis TE, Edwards V, Friedman SR, Rockwell R, Hoover D, Williams IT and Monterroso ER. **Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City.** *Am J Public Health.* 2001; **91**:23-30. | [PubMed Abstract](#) | [PubMed Full Text](#)
47. Magiorkinis G, Sypsa V, Magiorkinis E, Paraskevis D, Katsoulidou A, Belshaw R, Fraser C, Pybus OG and Hatzakis A. **Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics.** *PLoS Comput Biol.* 2013; **9**:e1002876. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
48. Smith BD, Jorgensen C, Zibbell JE and Beckett GA. **Centers for Disease Control and Prevention initiatives to prevent hepatitis C virus infection: a selective update.** *Clin Infect Dis.* 2012; **55** Suppl 1:S49-53. | [Article](#) | [PubMed](#)
49. Vickerman P, Martin N, Turner K and Hickman M. **Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings.** *Addiction.* 2012; **107**:1984-95. | [Article](#) | [PubMed](#)
50. Blackard JT. **HCV superinfection and reinfection.** *Antivir Ther.* 2012; **17**:1443-8. | [Article](#) | [PubMed](#)
51. Volk ML, Tocco R, Saini S and Lok AS. **Public health impact of antiviral therapy for hepatitis C in the United States.** *Hepatology.* 2009; **50**:1750-5. | [Article](#) | [PubMed](#)
52. New York State Department of Health, AIDS Institute. **HIV/AIDS Surveillance Annual Report: For Cases Diagnosed Through December 2008.** In *HIV/AIDS Surveillance Annual Report: For Cases Diagnosed Through December 2008*; 2010. | [Pdf](#)

Citation:

Hart-Malloy R and DiRienzo G. **A quasi-markov model for transmission and disease elimination: Hepatitis C among people who inject drugs.** *J Med Stat Inform.* 2014; **2**:8.
<http://dx.doi.org/10.7243/2053-7662-2-8>